دورية أكاديمية
Frequency of expression of RHAMM/CD168 in Egyptian patients with CML.
| العنوان: | Frequency of expression of RHAMM/CD168 in Egyptian patients with CML. |
|---|---|
| المؤلفون: | Gouda HM; The Department of Clinical & Chemical Pathology, Cairo University, Egypt. goudamed@hotmail.com, Abdel Mohsen MM |
| المصدر: | Journal of the Egyptian National Cancer Institute [J Egypt Natl Canc Inst] 2009 Jun; Vol. 21 (2), pp. 93-9. |
| نوع المنشور: | Comparative Study; Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: SpringerOpen Country of Publication: England NLM ID: 9424566 Publication Model: Print Cited Medium: Print ISSN: 1110-0362 (Print) Linking ISSN: 11100362 NLM ISO Abbreviation: J Egypt Natl Canc Inst Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2019- : London : SpringerOpen Original Publication: Cairo, Egypt : National Cancer Institute |
| مواضيع طبية MeSH: | Cell Proliferation*, Biomarkers, Tumor/*genetics , Extracellular Matrix Proteins/*genetics , Hyaluronan Receptors/*genetics , Leukemia, Myeloid, Chronic-Phase/*genetics, Adult ; Blast Crisis ; Case-Control Studies ; Female ; Fusion Proteins, bcr-abl/genetics ; Humans ; Leukemia, Myeloid, Chronic-Phase/blood ; Male ; Middle Aged ; Prognosis ; RNA, Messenger/genetics ; RNA, Neoplasm/genetics ; Reverse Transcriptase Polymerase Chain Reaction |
| مستخلص: | RHAMM/CD168 is a cell surface receptor for hyaluronan, a glycoaminoglycan that plays a fundamental role in cell growth, differentiation and motility. It is one of the leukemia-associated antigens (LAA) identified in patients with myeloid leukemias. We Aimed: at studying the frequency of expression of RHAMM/CD168 in Egyptian patients with CML, both in chronic phase and accelerated/blastic phase, as a potential target structure for cellular immunotherapies, and to compare it with available western records. Patients and Methods: RHAMM expression was tested by RT-PCR in peripheral blood mononuclear cells of 60 CML patients divided into 2 groups, group A: 44 chronic phase CML patients, group B: 16 accelerated/ blastic phase patients as well as 15 healthy volunteers. Our Results: Demonstrated that 14/44 (31.8%) of chronic CML patients showed positive RHAMM expression in contrast to 15/16 ( 93.7%) in the accelerated/blastic phase patients. Moreover within the chronic phase patients the RHAMM positive patients had a significantly higher level of bcr-abl/abl ratio. This highlighted the contribution of RHAMM expression with CML disease progression. Conclusion: Our work demonstrated a similar proportion of RHAMM expression in both Egyptian and western CML patients. This may pave the way for subsequent studies suggesting the concomitant use of RHAMM R3 peptide vaccination with conventional CML therapy especially in accelerated phase, in order to achieve complete molecular remission for our patient. |
| المشرفين على المادة: | 0 (Biomarkers, Tumor) 0 (Extracellular Matrix Proteins) 0 (Hyaluronan Receptors) 0 (RNA, Messenger) 0 (RNA, Neoplasm) 0 (hyaluronan-mediated motility receptor) EC 2.7.10.2 (Fusion Proteins, bcr-abl) |
| تواريخ الأحداث: | Date Created: 20101109 Date Completed: 20110224 Latest Revision: 20220309 |
| رمز التحديث: | 20231215 |
| PMID: | 21057560 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1110-0362 |
|---|